Formula I Compounds Targeting HCV NS5B Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, particularly for genotype 1, which has a low sustained virologic response rate and severe side effects, necessitating the development of improved antiviral drugs with better efficacy and safety profiles.
Innovation Solution
Development of novel compounds of formula I, which include pharmaceutically acceptable salts, specifically designed to target HCV, offering mechanisms of action that enhance binding, inhibition efficacy, target selectivity, solubility, and safety, potentially targeting the NS5B protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard therapy (pegylated alpha-interferon and ribavirin) is used for HCV treatment, then treatment coverage is provided, but sustained virologic response rate is low (approximately 50% for genotype 1) and severe side effects occur
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (formula I with various substituents R1-R6) that change the pharmacological parameters of antiviral activity and safety profile. The compounds represent a fundamental change in the therapeutic parameter space, moving from interferon-based therapy to novel small molecule inhibitors with improved efficacy and reduced side effects.
2Reliability
If genotype 1 HCV is targeted with current therapies, then treatment is provided, but treatment response is poor and elimination of the virus is achieved for only approximately 50% of patients
Solution Approach 1:
The patent extracts the problematic elements of current therapy (interferon, ribavirin) and replaces them with a novel compound class that specifically targets HCV replication. The compounds of formula I represent a purified, focused therapeutic approach that extracts the essential antiviral function while eliminating the side effects and limitations of combination therapy.
3Reliability
If novel compounds of formula I are developed to improve binding and inhibition efficacy, then antiviral activity is enhanced, but compound complexity increases
Solution Approach 1:
The patent applies local quality by designing compounds where specific substituent groups (R1-R6) at different positions of the core structure provide specialized functions. Each substituent can be optimized independently to enhance binding to specific viral targets, improve pharmacokinetic properties, or reduce off-target effects, allowing complex functionality to be distributed across modular structural elements.
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.